Valuation dashboard for Delcath Systems, Inc. (DCTH) with P/E 1467.87, P/B 4.78, EV/EBITDA 297.45 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects.
Analysis Summary
Delcath Systems, Inc. reported revenue of $85.2M in the most recent fiscal year, growing at a 5-year CAGR of 120.2%.
Trailing-twelve-month margins: gross margin 87.1%, operating margin -1.9%, net margin 0.6%.
At the current price of $16.22, DCTH trades at a P/E of 1467.87 and an ROE of 0.46%. Market capitalisation stands at $560M.
Balance sheet quality for DCTH: current ratio of 10.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 1467.87 |
| Price / Book | 4.78 |
| EV / EBITDA | 297.45 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-126.24 |
| vs Current Price | -878.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DCTH | Delcath Systems, Inc. | $560M | 1467.87 | 4.78 | 0.5% |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price
| Price | $16.22 |
| Market Cap | $560M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 0.46% |
| Return on Invested Capital | -0.60% |
| Return on Assets | 0.39% |
| Gross Margin | 87.05% |
| Operating Margin | -1.90% |
| Net Margin | 0.56% |
Related companies: AGL · BWAY · CERS · MASS · NAKA · NPCE · RXST
Explore sector: Healthcare · Medical - Devices
More sections of DCTH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks